| Year |
Citation |
Score |
| 2023 |
Spicer J, Basu B, Montes A, Banerji U, Kristeleit R, Miller R, Veal GJ, Corrigan CJ, Till SJ, Figini M, Canevari S, Barton C, Jones P, Mellor S, Carroll S, et al. Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial. Nature Communications. 14: 4180. PMID 37491373 DOI: 10.1038/s41467-023-39679-9 |
0.307 |
|
| 2023 |
Ghorani E, Quartagno M, Blackhall F, Gilbert DC, O'Brien M, Ottensmeier C, Pizzo E, Spicer J, Williams A, Badman P, Parmar MKB, Seckl MJ. REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment. The Lancet. Oncology. 24: e219-e227. PMID 37142383 DOI: 10.1016/S1470-2045(23)00095-5 |
0.305 |
|
| 2022 |
Hughes DJ, Kapiris M, Podvez Nevajda A, McGrath H, Stavraka C, Ahmad S, Taylor B, Cook GJR, Ghosh S, Josephs D, Pintus E, Gennatas S, Bille A, Ryanna K, Santis G, ... ... Spicer J, et al. Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World Study. Cancers. 14. PMID 36551542 DOI: 10.3390/cancers14246056 |
0.348 |
|
| 2020 |
Russell B, Moss C, Papa S, Irshad S, Ross P, Spicer J, Kordasti S, Crawley D, Wylie H, Cahill F, Haire A, Zaki K, Rahman F, Sita-Lumsden A, Josephs D, et al. Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London. Frontiers in Oncology. 10: 1279. PMID 32903324 DOI: 10.3389/Fonc.2020.01279 |
0.38 |
|
| 2020 |
Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, Gilligan D, Cave J, O'Rourke N, Brewster A, Toy E, Spicer J, Jain P, Dangoor A, Mackean M, et al. Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer. Nature. PMID 32887973 DOI: 10.1038/S41586-020-2656-3 |
0.341 |
|
| 2020 |
Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, Rachet B, Aggarwal A. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. The Lancet. Oncology. PMID 32702310 DOI: 10.1016/S1470-2045(20)30388-0 |
0.31 |
|
| 2020 |
Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, Gilligan D, Cave J, O'Rourke N, Brewster A, Toy E, Spicer J, Jain P, Dangoor A, Mackean M, et al. The National Lung Matrix Trial of personalized therapy in lung cancer. Nature. PMID 32669708 DOI: 10.1038/S41586-020-2481-8 |
0.415 |
|
| 2020 |
Torricelli F, Saxena A, Nuamah R, Neat M, Harling L, Ng W, Spicer J, Ciarrocchi A, Bille A. Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy. European Journal of Cancer (Oxford, England : 1990). 132: 104-111. PMID 32339978 DOI: 10.1016/J.Ejca.2020.03.002 |
0.354 |
|
| 2020 |
Spicer J, Basu B, Montes A, Banerji U, Kristeleit R, Veal GJ, Corrigan C, Till S, Nintos G, Brier T, Funingana IG, Ang JE, Zaki K, Griffin A, Barton C, et al. Abstract CT141: Phase 1 trial of MOv18, a first-in-class IgE antibody therapy for cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct141 |
0.428 |
|
| 2020 |
Powell-Tuck C, Crawley D, Karapanagiotou E, Montes A, Holden S, Dawson J, Josephs D, Spicer J, Ghosh S. Psychological experiences in patients with lung cancer taking targeted therapies Lung Cancer. 139. DOI: 10.1016/S0169-5002(20)30221-X |
0.381 |
|
| 2019 |
Spicer J, Provencio M, Garrido Lopez P, Bosch-Barrera J, de Castro Carpeño FJ, Felip E, Trigo J, Viteri S, Coart E, Schmidt E, Christiansen AV, Zocca MB, Andersen MH, Ehrnrooth E, Paz-Ares L. An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: ii65-ii66. PMID 32131320 DOI: 10.1093/Annonc/Mdz063.078 |
0.435 |
|
| 2019 |
Macpherson IR, Spiliopoulou P, Rafii S, Saggese M, Baird RD, Garcia-Corbacho J, Italiano A, Bonneterre J, Campone M, Cresti N, Posner J, Takeda Y, Arimura A, Spicer J. A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. Breast Cancer Research : Bcr. 22: 1. PMID 31892325 DOI: 10.1186/S13058-019-1178-0 |
0.393 |
|
| 2019 |
Fenwick JD, Landau DB, Baker A, Bates AT, Eswar C, Garcia-Alonso A, Harden SV, Illsley MC, Laurence V, Malik Z, Mayles WPM, Miles E, Mohammed N, Spicer J, Wells P, et al. Long-term results from the IDEAL-CRT phase 1/2 trial of isotoxically dose-escalated radiation therapy and concurrent chemotherapy for stage II/III non-small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 31809876 DOI: 10.1016/J.Ijrobp.2019.11.397 |
0.406 |
|
| 2019 |
Khan M, Spicer J. The Evolving Landscape of Cancer Therapeutics. Handbook of Experimental Pharmacology. PMID 31792681 DOI: 10.1007/164_2019_312 |
0.385 |
|
| 2019 |
Marabelle A, Baurain J, Awada A, Kristeleit RS, Loirat D, Jossang DE, Jebsen NL, Sveinbjornsson B, Rekdal Ø, Gjerstad VS, Brunsvig P, Galon J, Hermitte F, Patel H, Spicer J. Abstract CT069: A Phase I study of the oncolytic peptide LTX-315 generatesde novoT-cell responses and clinical benefit in patients with advanced melanoma Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct069 |
0.415 |
|
| 2019 |
Hughes DJ, Chand G, Josephs D, Harries M, Papa S, Spicer J, Ting HH, Goh V, Cook G. 173TiP PECan Study, Imaging PD-L1 in Cancer: A Tool for Measuring Response to Immunotherapy? Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz450.010 |
0.303 |
|
| 2019 |
Dillon M, Guevara J, Mohammed K, Smith SA, Dean E, McLellan L, Boylan Z, Spicer J, Forster MD, Harrington KJ. A phase I study of ATR inhibitor, AZD6738, as monotherapy in advanced solid tumours (PATRIOT part A, B) Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz244.012 |
0.354 |
|
| 2019 |
Torricelli F, Saxena A, Nuamah R, Neat M, Harling L, Ng W, Spicer J, Ciarrocchi A, Bille A. MA12.05 Genomic Analysis of Long Term Malignant Pleura Mesothelioma Patients Treated with Palliative Chemotherapy Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.595 |
0.301 |
|
| 2019 |
Felip E, Brunsvig P, Helland Å, Viñolas N, Aix S, Carcereny E, Gomez MD, Perez JMT, Arriola E, Campelo RG, Spicer J, Thompson J, Granados ALO, Holt R, Smethurst D, et al. MA03.06 Efficacy Results of Selective AXL Inhibitor Bemcentinib with Pembrolizumab Following Chemotherapy in Patients with NSCLC Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.515 |
0.396 |
|
| 2019 |
Middleton G, Popat S, Fletcher P, Summers YJ, Greystoke A, Gilligan D, Cave J, O'Rourke N, Brewster A, Toy E, Spicer J, Savage J, Sharpe R, Yap T, Swanton C, et al. PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.060 |
0.385 |
|
| 2018 |
Concin N, Vergote IB, Lassen UN, Drew Y, Machiels JP, Arkenau HT, Forster MD, Jones R, Johnson ML, Slomovitz BM, Spicer J, Cornez N, Gennigens C, Coleman RL, Windfeld K, et al. A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii344. PMID 32136816 DOI: 10.1093/Annonc/Mdy285.170 |
0.356 |
|
| 2018 |
Harling L, Kolokotroni SM, Nair A, Smelt J, King J, Routledge T, Spicer J, Ng W, Bille A. Differential Survival characteristics of sarcomatoid subtype biphasic pleural mesothelioma. The Annals of Thoracic Surgery. PMID 30389446 DOI: 10.1016/J.Athoracsur.2018.09.019 |
0.318 |
|
| 2018 |
Plummer R, Verheul HM, De Vos FYFL, Leunen K, Molife LR, Rolfo C, Grundtvig-Sørensen P, De Grève J, Rottey S, Jerusalem G, Italiano A, Spicer J, Dirix L, Goessl C, Birkett J, et al. Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours. Advances in Therapy. PMID 30324586 DOI: 10.1007/S12325-018-0804-Z |
0.388 |
|
| 2018 |
Arkenau HT, Italiano A, Mak G, Toulmonde M, Baird RD, Garcia-Corbacho J, Plummer R, Flynn M, Forster M, Wilson RH, Tosi D, Adenis A, Donaldson K, Posner J, Kawabata I, ... ... Spicer J, et al. An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. European Journal of Cancer (Oxford, England : 1990). 103: 17-23. PMID 30196106 DOI: 10.1016/J.Ejca.2018.07.134 |
0.386 |
|
| 2018 |
O'Brien MER, Sarker D, Bhosle J, Thillai K, Yap TA, Uttenreuther-Fischer M, Pemberton K, Jin X, Wiebe S, de Bono J, Spicer J. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. PMID 30088048 DOI: 10.1007/S00280-018-3661-1 |
0.367 |
|
| 2018 |
Basu B, Krebs MG, Sundar R, Wilson RH, Spicer J, Jones R, Brada M, Talbot DC, Steele N, Ingles Garces AH, Brugger W, Harrington EA, Evans J, Hall E, Tovey H, et al. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30016392 DOI: 10.1093/Annonc/Mdy245 |
0.42 |
|
| 2018 |
Møller H, Coupland VH, Tataru D, Peake MD, Mellemgaard A, Round T, Baldwin DR, Callister MEJ, Jakobsen E, Vedsted P, Sullivan R, Spicer J. Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients. Thorax. PMID 29511056 DOI: 10.1136/Thoraxjnl-2017-210710 |
0.412 |
|
| 2018 |
Tokaca N, Pouptsis A, Karapanagiotou E, Spicer J, Halkyard E, Blackhall F, Summers Y, Greystoke A, Bhosle J, Jones A, Newsom-Davis T, Nicolson M, O’Brien M, Yousaf N, Popat S. Retrospective analysis of outcomes in UK patients with advanced NSCLC and ROS1 rearrangement Lung Cancer. 115. DOI: 10.1016/S0169-5002(18)30130-2 |
0.35 |
|
| 2018 |
Popat S, Januszewski A, Hughes L, O'Brien M, Ahmad T, Lewanski C, Dernedde U, Jankowska P, Mulatero C, Shah R, Hicks J, Geldart T, Cominos M, Gray G, Spicer J, et al. P1.13-17 Multicentre Phase II Trial of First-Line Afatinib in Patients with Suspected/Confirmed EGFR Mutant NSCLC: ctDNA and Long-Term Efficacy Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.874 |
0.361 |
|
| 2018 |
Arce-Lara C, Arriola E, Brunsvig P, Carcereny E, Domine M, Dragnev K, Felip E, Campelo RG, Krebs M, Paz-Ares L, Aix SP, Spicer J, Trigo JM, Segarra NV, Holt R, et al. P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in Patients with Advanced NSCLC Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.1251 |
0.333 |
|
| 2017 |
Temam S, Spicer J, Farzaneh F, Soria JC, Oppenheim D, McGurk M, Hollebecque A, Sarini J, Hussain K, Soehrman Brossard S, Manenti L, Evers S, Delmar P, Di Scala L, Mancao C, et al. An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28950289 DOI: 10.1093/Annonc/Mdx489 |
0.391 |
|
| 2017 |
Ferry D, Billingham L, Jarrett H, Dunlop D, Woll PJ, Nicolson M, Shah R, Thompson J, Spicer J, Muthukumar D, Skailes G, Leonard P, Chetiyawardana AD, Wells P, Lewanski C, et al. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer (Oxford, England : 1990). 83: 302-312. PMID 28780466 DOI: 10.1016/J.Ejca.2017.05.037 |
0.466 |
|
| 2017 |
Beddowes E, Spicer J, Chan PY, Khadeir R, Corbacho JG, Repana D, Steele JP, Schmid P, Szyszko T, Cook G, Diaz M, Feng X, Johnston A, Thomson J, Sheaff M, et al. Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016713230. PMID 28388291 DOI: 10.1200/Jco.2016.71.3230 |
0.397 |
|
| 2017 |
Wilson RH, Evans TJ, Middleton MR, Molife LR, Spicer J, Dieras V, Roxburgh P, Giordano H, Jaw-Tsai S, Goble S, Plummer R. A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. British Journal of Cancer. PMID 28222073 DOI: 10.1038/Bjc.2017.36 |
0.401 |
|
| 2017 |
Rafii S, Macpherson I, Baird R, Saggese M, Spiliopoulou P, Kumar S, Italiano A, Bonneterre J, Campone M, Cresti N, Posner J, Takeda Y, Arimura A, Spicer J. Abstract P4-21-08: A phase I/II of S-222611, a reversible EGFR and HER2 inhibitor, combined with trastuzumab +/- chemotherapy in patients with HER2-positive metastatic breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P4-21-08 |
0.393 |
|
| 2017 |
Papa S, Adami A, Metoudi M, Achkova D, Schalkwyk Mv, Pereira AP, Bosshard-Carter L, Whilding L, Stegen Svd, Davies DM, Guerrero-Urbano T, Jeannon JP, Spicer J, Maher J. Abstract CT118: T4 immunotherapy of head and neck squamous cell carcinoma using pan-ErbB targeted CAR T-cells Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct118 |
0.315 |
|
| 2017 |
Baurain J, Awada A, Brunsvig PF, Kristeleit R, Loirat D, Jøssang DE, Zitvogel L, Kroemer G, Marabelle A, Rekdal Ø, Sveinbjørnsson B, Wold H, Nicolaisen B, Saunders A, Spicer J. Abstract CT108: A phase I dose escalation study of intra-tumoral LTX-315 as monotherapy or in combination with either ipilimumab or pembrolizumab in patients with transdermally accessible tumors (NCT01986426) Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct108 |
0.376 |
|
| 2017 |
Vergote I, Dean EJ, Lassen U, Bono JD, Drew Y, Machiels J, Nielsen D, Arkenau H, Forster M, Jones R, Slomovitz B, Spicer J, Johnson M, Cornez N, Gennigens C, et al. 9310 A phase IIa study of tisotumab vedotin (HuMax (R)-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer. Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx372.001 |
0.358 |
|
| 2017 |
Hunter S, Nickless G, Ghosh S, Lal R, Merrick SA, Montes A, Smith D, Spicer J, Karapanagiotou E. 72: Treatment outcomes with tyrosine kinase inhibitors in patients with uncommon EGFR mutations in non-small cell lung cancer Lung Cancer. 103. DOI: 10.1016/S0169-5002(17)30122-8 |
0.398 |
|
| 2017 |
Tokaca N, Crawford MS, Greystoke A, Appel W, Lal R, Steele N, Ali C, Bezecny P, Fernando S, Karapanagiotou E, Skailes G, Dorey N, Harrow S, Bhosle J, Khan O, ... ... Spicer J, et al. 69: Outcomes with nintedanib and docetaxel in patients with relapsed NSCLC adenocarcinoma treated within the UK Nintedanib Individual Patient Supply programme Lung Cancer. 103. DOI: 10.1016/S0169-5002(17)30119-8 |
0.365 |
|
| 2017 |
Kindler HL, Novello S, Fennell D, Blumenschein G, Bearz A, Ceresoli G, Aerts J, Spicer J, Taylor P, Greystoke A, Nackaerts K, Calabro L, Burgers S, Jennens R, Sporchia A, et al. OA 02.01 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.328 |
0.33 |
|
| 2017 |
Bille A, Kolokotroni SM, King J, Smelt J, Ashrafian L, Spicer J, Routledge T, Ng W. P3.03-037 Impact of Sarcomatoid Component in Patients with Biphasic Mesothelioma: Review of 118 Patients: Topic: Mesothelioma Clinical Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1936 |
0.313 |
|
| 2017 |
Krebs M, Spicer J, Steele N, Talbot D, Brada M, Wilson R, Jones R, Basu B, Dawes J, Parmar M, Purchase B, Turner A, Hall E, Tovey H, Banerji U, et al. P3.02c-003 TAX-TORC: The novel combination of weekly paclitaxel and the dual mTORC1/2 inhibitor AZD2014 for the treatment of squamous NSCLC. Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1798 |
0.317 |
|
| 2017 |
Popat S, Hughes L, O'Brien M, Ahmad T, Lewanski C, Dernedde U, Jankowska P, Mulatero C, Shah R, Hicks J, Geldart T, Cominos M, Gray G, Spicer J, Bell K, et al. P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial): Topic: EGFR Clinical Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1713 |
0.385 |
|
| 2016 |
Jensen-Jarolim E, Bax HJ, Bianchini R, Capron M, Corrigan C, Castells M, Dombrowicz D, Daniels-Wells TR, Fazekas J, Fiebiger E, Gatault S, Gould HJ, Janda J, Josephs DH, Karagiannis P, ... ... Spicer JF, et al. AllergoOncology - The impact of Allergy in Oncology. EAACI Position Paper. Allergy. PMID 28032353 DOI: 10.1111/All.13119 |
0.324 |
|
| 2016 |
Lee SM, Falzon M, Blackhall F, Spicer J, Nicolson M, Chaudhuri A, Middleton G, Ahmed S, Hicks J, Crosse B, Napier M, Singer JM, Ferry D, Lewanski C, Forster M, et al. Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016681841. PMID 27893326 DOI: 10.1200/Jco.2016.68.1841 |
0.432 |
|
| 2016 |
Spicer J, Irshad S, Ang JE, Enting D, Kristeleit R, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J. A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. PMID 27872953 DOI: 10.1007/S00280-016-3189-1 |
0.345 |
|
| 2016 |
Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S, Shamash J, Phillips MM, Luong P, Payne S, Hillman P, Ellis S, Szyszko T, et al. Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial. Jama Oncology. PMID 27584578 DOI: 10.1001/Jamaoncol.2016.3049 |
0.403 |
|
| 2016 |
Landau DB, Hughes L, Baker A, Bates AT, Bayne MC, Counsell N, Garcia-Alonso A, Harden SV, Hicks JD, Hughes SR, Illsley MC, Khan I, Laurence V, Malik Z, Mayles H, ... ... Spicer J, et al. IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 27296040 DOI: 10.1016/J.Ijrobp.2016.03.031 |
0.433 |
|
| 2016 |
Thayaparan T, Stegen SJCvd, Puri ACPP, Petrovic RM, Spicer J, Maher J. Abstract A075: Immunotherapy of malignant pleural mesothelioma using cMET specific T-cells Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A075 |
0.351 |
|
| 2016 |
Baird R, Arkenau H, Deva S, Cresti N, Garcia-Corbacho J, Hogarth L, Frenkel E, Kawaguchi K, Arimura A, Donaldson K, Posner J, Sarker D, Jodrell D, Plummer R, Spicer J, et al. Abstract P4-14-26: Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain metastases Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P4-14-26 |
0.441 |
|
| 2016 |
Rush H, Roca J, Dalby M, Smith D, Lal R, Spicer J, Montes A, Karapanagiotou E. 77 Systemic therapy is safe and effective in octogenarians with advanced lung cancer Lung Cancer. 91. DOI: 10.1016/S0169-5002(16)30094-0 |
0.36 |
|
| 2015 |
Wu Y, Spicer J. Nedaplatin: a new platinum for squamous lung cancer? The Lancet. Oncology. PMID 26522336 DOI: 10.1016/S1470-2045(15)00400-3 |
0.358 |
|
| 2015 |
Suder A, Ang JE, Kyle F, Harris D, Rudman S, Kristeleit R, Solca F, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J, Spicer J. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. European Journal of Cancer (Oxford, England : 1990). 51: 2275-84. PMID 26296295 DOI: 10.1016/J.Ejca.2015.07.041 |
0.407 |
|
| 2015 |
Plummer R, Swaisland H, Leunen K, van Herpen CM, Jerusalem G, De Grève J, Lolkema MP, Soetekouw P, Mau-Sørensen M, Nielsen D, Spicer J, Fielding A, So K, Bannister W, Molife LR. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology. PMID 26242220 DOI: 10.1007/S00280-015-2836-2 |
0.364 |
|
| 2015 |
Ramalingam S, Goss G, Rosell R, Schmid-Bindert G, Zaric B, Andric Z, Bondarenko I, Komov D, Ceric T, Khuri F, Samarzija M, Felip E, Ciuleanu T, Hirsh V, Wehler T, ... Spicer J, et al. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 1741-8. PMID 25997818 DOI: 10.1093/Annonc/Mdv220 |
0.453 |
|
| 2015 |
Lang-Lazdunski L, Bille A, Papa S, Marshall S, Lal R, Galeone C, Landau D, Steele J, Spicer J. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience. The Journal of Thoracic and Cardiovascular Surgery. 149: 558-65; discussion 5. PMID 25726878 DOI: 10.1016/J.Jtcvs.2014.10.041 |
0.368 |
|
| 2015 |
Gao F, Pfeifer E, Farah H, Karampini E, Dua D, Kamal N, Cane P, Tobal K, Sethi T, Spicer J, McCaughan F. Microdroplet digital PCR: detection and quantitation of biomarkers in archived tissue and serial plasma samples in patients with lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: 212-7. PMID 25654729 DOI: 10.1097/Jto.0000000000000349 |
0.38 |
|
| 2015 |
Shapiro GI, Bell-McGuinn KM, Molina JR, Bendell J, Spicer J, Kwak EL, Pandya SS, Millham R, Borzillo G, Pierce KJ, Han L, Houk BE, Gallo JD, Alsina M, Braña I, et al. First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1888-95. PMID 25652454 DOI: 10.1158/1078-0432.Ccr-14-1306 |
0.427 |
|
| 2015 |
Spicer J, Baird R, Suder A, Cresti N, Corbacho JG, Hogarth L, Frenkel E, Matsumoto S, Kawabata I, Donaldson K, Posner J, Sarker D, Jodrell D, Plummer R. Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours. European Journal of Cancer (Oxford, England : 1990). 51: 137-45. PMID 25434923 DOI: 10.1016/J.Ejca.2014.11.003 |
0.395 |
|
| 2015 |
Roulstone V, Khan K, Pandha HS, Rudman S, Coffey M, Gill GM, Melcher AA, Vile R, Harrington KJ, de Bono J, Spicer J. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1305-12. PMID 25424857 DOI: 10.1158/1078-0432.Ccr-14-1770 |
0.31 |
|
| 2015 |
Karampini E, Farah H, Kamal N, Cane P, Moorhead J, Pomplun S, King J, Sethi T, Spicer J, McCaughan F. Circulating biomarkers and tumour molecular profiling in patients with non-small cell lung cancer European Respiratory Journal. DOI: 10.1183/13993003.Congress-2015.Pa525 |
0.41 |
|
| 2015 |
Spicer J, Tischer B, Peters M. P176 Epidermal Growth Factor Receptor (EGFR) Mutation Testing and Treatment Choice in Advanced Non-small Cell Lung Cancer (NSCLC): UK Findings from a Global Survey Thorax. 70. DOI: 10.1136/Thoraxjnl-2015-207770.313 |
0.372 |
|
| 2015 |
Karampini E, Muhith A, Farah H, King J, Cane P, Spicer J, McCaughan F. S105 Microdroplet digital PCR for the longitudinal monitoring of circulating tumour DNA biomarkers in unselected patients with advanced lung cancer Thorax. 70. DOI: 10.1136/Thoraxjnl-2015-207770.111 |
0.381 |
|
| 2015 |
Charlton P, Josephides E, Karapanagiotou E, Montes A, Spicer J, Lal R. 131Pduration And Tolerance Of Maintenance Pemetrexed (Mpem) Treatment For Advanced Non-Small Cell Lung Cancer Annals of Oncology. 26. DOI: 10.1093/Annonc/Mdv050.35 |
0.397 |
|
| 2015 |
Charlton P, Karapanagiotou E, Montes A, Spicer J, Lal R. 60: Discontinuation of maintenance pemetrexed (mPEM) in non-small cell lung cancer (NSCLC) due to renal failure Lung Cancer. 87. DOI: 10.1016/S0169-5002(15)50060-3 |
0.346 |
|
| 2015 |
Lang-Lazdunski L, Bille A, Lal R, Landau D, Spicer J. 56: Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy and systemic chemotherapy in malignant pleural mesothelioma. Experience in 100 consecutive patients Lung Cancer. 87. DOI: 10.1016/S0169-5002(15)50056-1 |
0.336 |
|
| 2015 |
Karampini E, Farah H, Mills G, Kamal N, Tobal K, Cane P, Muirhead J, Pomplun S, King JE, Sethi T, McCaughan F, Spicer J. 8: Tumour molecular profiling and quantitative detection of circulating biomarkers in patients with lung cancer Lung Cancer. 87. DOI: 10.1016/S0169-5002(15)50008-1 |
0.388 |
|
| 2014 |
Lee S, Blackhall FH, Spicer J, Nicolson MC, Chaudhuri A, Middleton G, Ahmed S, Hicks J, Crosse B, Napier M, Singer J, Ferry D, Lewanski C, Rolls S, Iles N, et al. 169OET: A RANDOMIZED, MULTICENTER, PHASE III TRIAL OF PLATINUM VERSUS NONPLATINUM CHEMOTHERAPY, AFTER ERCC1 STRATIFICATION, IN PATIENTS WITH ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv59. PMID 28170639 DOI: 10.1093/Annonc/Mdu326.3 |
0.373 |
|
| 2014 |
Blagden S, Omlin A, Olmin A, Josephs D, Stavraka C, Zivi A, Pinato DJ, Anthoney A, Decordova S, Swales K, Riisnaes R, Pope L, Noguchi K, Shiokawa R, Inatani M, ... ... Spicer J, et al. First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5908-17. PMID 25231405 DOI: 10.1158/1078-0432.Ccr-14-1315 |
0.377 |
|
| 2014 |
Camidge DR, Berge EM, Doebele RC, Ballas MS, Jahan T, Haigentz M, Hoffman D, Spicer J, West H, Lee P, Yang L, Joshi A, Gao L, Yurasov S, Mita A. A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 1532-9. PMID 25170639 DOI: 10.1097/Jto.0000000000000273 |
0.448 |
|
| 2014 |
Sharrocks K, Spicer J, Camidge DR, Papa S. The impact of socioeconomic status on access to cancer clinical trials. British Journal of Cancer. 111: 1684-7. PMID 25093493 DOI: 10.1038/Bjc.2014.108 |
0.401 |
|
| 2014 |
Michalarea V, Calcasola M, Cane P, Tobal K, Izatt L, Spicer J. EGFR-mutated lung cancer in Li-Fraumeni syndrome. Lung Cancer (Amsterdam, Netherlands). 85: 485-7. PMID 25047674 DOI: 10.1016/J.Lungcan.2014.06.017 |
0.362 |
|
| 2014 |
Corrigan A, Walker JL, Wickramasinghe S, Hernandez MA, Newhouse SJ, Folarin AA, Lewis CM, Sanderson JD, Spicer J, Marinaki AM. Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations. The Pharmacogenomics Journal. 14: 411-7. PMID 24732178 DOI: 10.1038/Tpj.2014.13 |
0.375 |
|
| 2014 |
Lüchtenborg M, Riaz SP, Lim E, Page R, Baldwin DR, Jakobsen E, Vedsted P, Lind M, Peake MD, Mellemgaard A, Spicer J, Lang-Lazdunski L, Møller H. Survival of patients with small cell lung cancer undergoing lung resection in England, 1998-2009. Thorax. 69: 269-73. PMID 24172710 DOI: 10.1136/Thoraxjnl-2013-203884 |
0.398 |
|
| 2014 |
Fennell D, Antonov A, Martins ML, Popat S, Ramalingam SS, Spicer J, Vukovic VM, El-Hariry I, Reichert V, Rosell R. Abstract 4657: Evaluation of genomic profiling in the GALAXY-1 (NCT01348126), a randomized Phase 2b study of ganetespib in combination with docetaxel versus docetaxel alone as second line therapy in patients with advanced NSCLC Cancer Research. 74: 4657-4657. DOI: 10.1158/1538-7445.Am2014-4657 |
0.402 |
|
| 2014 |
Thayaparan T, Stegen Svd, Pereira ACP, Petrovic R, Spicer J, Maher J. Abstract 2800: Immunotherapy of malignant pleural mesothelioma using MET specific t – cells Cancer Research. 74: 2800-2800. DOI: 10.1158/1538-7445.Am2014-2800 |
0.352 |
|
| 2014 |
Lüchtenborg M, Riaz SP, Lim E, Page R, Baldwin DR, Jakobsen E, Vedsted P, Lind MJ, Peake MD, Mellemgaard A, Spicer J, Lang-Lazdunski L, Møller H. 187 Survival of small cell lung cancer patients undergoing lung resection in England 1998-2009 Lung Cancer. 83. DOI: 10.1016/S0169-5002(14)70188-6 |
0.317 |
|
| 2014 |
Thillai K, Donovan V, Soultati A, Kandasamy R, Schalkwyk MV, Mather R, Najaryan N, Spicer J, Montes A, Lal R, Benepal T. 68 The prevalence of hyponatraemia amongst patients with newly diagnosed thoracic malignancies Lung Cancer. 83. DOI: 10.1016/S0169-5002(14)70068-6 |
0.391 |
|
| 2014 |
Thillai K, Soultati A, Lawrence H, Spicer J, Lal R, Montes A. 55 Lung cancer presenting with symptomatic bone metastases: Are we doing enough? Lung Cancer. 83. DOI: 10.1016/S0169-5002(14)70055-8 |
0.324 |
|
| 2014 |
Thillai K, Soultati A, Montes A, Karapanagiotou E, Spicer J, Lal R. 25 A retrospective analysis of patients with advanced EGFR mutated lung cancer treated with either first line erlotinib or gefitinib Lung Cancer. 83. DOI: 10.1016/S0169-5002(14)70026-1 |
0.41 |
|
| 2014 |
Dua D, Montes A, Warner M, Spicer J, Lal R. 24 Outcome in metastatic NSCLC without EGFR and KRAS mutation treated with second line erlotinib Lung Cancer. 83. DOI: 10.1016/S0169-5002(14)70025-X |
0.316 |
|
| 2014 |
Beddowes EJ, Hatipoglu E, Montes A, Spicer J, Moller H, Lal R. 16 Characterising the use and impact of bisphosphonates in patients with bone metastases from non-small cell lung cancer; a single centre experience Lung Cancer. 83. DOI: 10.1016/S0169-5002(14)70017-0 |
0.373 |
|
| 2014 |
Gao F, Dua D, Pfeifer E, Farah H, Tobal K, Cane P, Spicer J, McCaughan F. 6 Microdroplet digital PCR in detecting mutational events in cell-free DNA in patients with lung cancer – a pilot study Lung Cancer. 83. DOI: 10.1016/S0169-5002(14)70007-8 |
0.368 |
|
| 2014 |
Papa S, Emami-Shahri N, Liu Z, Petrausch U, Mullen G, Spicer J, Maher J. Development of PSMA-specific immunotherapy for prostate cancer with PIN4 gene-modified T cells The Lancet. 383: S77. DOI: 10.1016/S0140-6736(14)60340-8 |
0.32 |
|
| 2013 |
Molife LR, Rudman SM, Alam S, Tan DS, Kristeleit H, Middleton G, Propper D, Bent L, Stopfer P, Uttenreuther-Fischer M, Wallenstein G, de Bono J, Spicer J. Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. Cancer Chemotherapy and Pharmacology. 72: 1213-22. PMID 24085260 DOI: 10.1007/S00280-013-2286-7 |
0.383 |
|
| 2013 |
Spicer J, Moller H, Papa S. Reply to A. Surbone et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2833. PMID 24058929 DOI: 10.1200/Jco.2013.49.6687 |
0.317 |
|
| 2013 |
Josephs DH, Fisher DS, Spicer J, Flanagan RJ. Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring. Therapeutic Drug Monitoring. 35: 562-87. PMID 24052062 DOI: 10.1097/Ftd.0B013E318292B931 |
0.339 |
|
| 2013 |
Bille A, Chicklore S, Okiror L, Cook GJ, Spicer J, Landau D, Lang-Lazdunski L. Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication. Nuclear Medicine Communications. 34: 1075-83. PMID 23963351 DOI: 10.1097/Mnm.0B013E3283653862 |
0.309 |
|
| 2013 |
Papa S, Popat S, Shah R, Prevost AT, Lal R, McLennan B, Cane P, Lang-Lazdunski L, Viney Z, Dunn JT, Barrington S, Landau D, Spicer J. Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 783-7. PMID 23571475 DOI: 10.1097/Jto.0B013E31828C2B26 |
0.405 |
|
| 2013 |
Simon ST, Higginson IJ, Benalia H, Gysels M, Murtagh FE, Spicer J, Bausewein C. Episodes of breathlessness: types and patterns - a qualitative study exploring experiences of patients with advanced diseases. Palliative Medicine. 27: 524-32. PMID 23486931 DOI: 10.1177/0269216313480255 |
0.304 |
|
| 2013 |
Yap TA, Arkenau HT, Camidge DR, George S, Serkova NJ, Gwyther SJ, Spratlin JL, Lal R, Spicer J, Desouza NM, Leach MO, Chick J, Poondru S, Boinpally R, Gedrich R, et al. First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 909-19. PMID 23403628 DOI: 10.1158/1078-0432.Ccr-12-2258 |
0.368 |
|
| 2013 |
Lassen U, Miller WH, Hotte S, Evans TR, Kollmansberger C, Adamson D, Nielsen DL, Spicer J, Chen E, Meyer T, Brown K, Rafi R, Sawyer MB. Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours. Cancer Chemotherapy and Pharmacology. 71: 543-9. PMID 23196640 DOI: 10.1007/S00280-012-2038-0 |
0.344 |
|
| 2013 |
Shapiro G, Kristeleit R, Middleton M, Burris H, Molife LR, Evans J, Wilson R, LoRusso P, Spicer J, Dieras V, Patel M, Dominy E, Simpson D, Giordano H, Allen AR, et al. Abstract A218: Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A218 |
0.373 |
|
| 2013 |
Baird R, Cresti N, Beddowes E, Saggese M, Flynn M, Corbacho JG, Gao F, Lemech C, Donaldson K, Posner J, Kawabata I, Forster M, Arkenau H, Plummer R, Jodrell D, ... Spicer J, et al. Abstract P4-12-24: Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated HER2-positive metastatic breast cancer Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-12-24 |
0.396 |
|
| 2013 |
Compton S, Michalarea V, Pintus E, Thomas R, Colvin M, Tindale-Paul P, Eestila S, Montes A, Spicer J, Lal R. 129 Treating non small cell lung cancer with erlotinib: the Nurse Led clinic experience Lung Cancer. 79. DOI: 10.1016/S0169-5002(13)70129-6 |
0.346 |
|
| 2013 |
Corrigan A, Lal R, Wickramasinghe S, Whelan S, Sanderson J, Marinaki A, Spicer J. 31 Testing for association between TPMT, COMT and NOX3 variants and the onset of ototoxicity in lung cancer patients treated with platinum chemotherapy Lung Cancer. 79. DOI: 10.1016/S0169-5002(13)70031-X |
0.411 |
|
| 2013 |
Moss C, Cane P, Mclean E, Santis G, Tobal K, Spicer J. 13 Acquired resistance to EGFR inhibition: evolution from adenocarcinoma to small cell lung cancer (SCLC) Lung Cancer. 79. DOI: 10.1016/S0169-5002(13)70013-8 |
0.374 |
|
| 2012 |
Enting D, Spicer J. EGFR inhibition and more: a new generation growing up. Journal of Thoracic Disease. 4: 553-5. PMID 23205276 DOI: 10.3978/J.Issn.2072-1439.2012.10.04 |
0.362 |
|
| 2012 |
Pennycuick A, Simpson T, Crawley D, Lal R, Santis G, Cane P, Tobal K, Spicer J. Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small cell lung cancer. International Journal of Clinical Practice. 66: 748-752. PMID 22805266 DOI: 10.1111/J.1742-1241.2012.02961.X |
0.319 |
|
| 2012 |
Bille A, Belcher E, Raubenheimer H, Landau D, Cane P, Spicer J, Lang-Lazdunski L. Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy's and St Thomas' hospitals. General Thoracic and Cardiovascular Surgery. 60: 289-96. PMID 22453539 DOI: 10.1007/S11748-011-0915-9 |
0.342 |
|
| 2012 |
Lang-Lazdunski L, Bille A, Lal R, Cane P, McLean E, Landau D, Steele J, Spicer J. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 737-43. PMID 22425923 DOI: 10.1097/Jto.0B013E31824Ab6C5 |
0.331 |
|
| 2012 |
Jamal-Hanjani M, Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 938-44. PMID 22167408 DOI: 10.1158/1078-0432.Ccr-11-2529 |
0.375 |
|
| 2012 |
Riaz SP, Lüchtenborg M, Coupland VH, Spicer J, Peake MD, Møller H. Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer (Amsterdam, Netherlands). 75: 280-4. PMID 21893364 DOI: 10.1016/J.Lungcan.2011.08.004 |
0.358 |
|
| 2012 |
Karagiannis P, Gilbert AE, Dodev T, Josephs DH, Ali N, Dafou D, Ainali C, Koers A, Tsoka S, Kaye SB, Spicer J, Gould HJ, Beavil A, Nestle FO, Karagiannis SN. Abstract 2524: Antibodies of the IgG and IgE classes against the melanoma-associated antigen HMW-MAA: Investigating a new therapeutic approach Cancer Research. 72: 2524-2524. DOI: 10.1158/1538-7445.Am2012-2524 |
0.324 |
|
| 2012 |
Camidge DR, Doebele RC, Ballas M, Jahan T, Haigentz M, Hoffman D, Spicer J, West H, Yurasov S, Mita AC. Final Results of a Phase 2, Open-Label Study of Ramucirumab (IMC-1121B; RAM), an IGG1 MAB Targeting Vegfr-2, with Paclitaxel and Carboplatin as First-Line Therapy in Patients (PTS) with Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) (NCT00735696) Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)33884-9 |
0.34 |
|
| 2012 |
Noor AM, Vizor S, McLennan B, Sarker D, Moller H, Spicer J, Papa S. The Impact of Patient Socio-Econonomic Status on Access to Early Phase Cancer Trials Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)33040-4 |
0.389 |
|
| 2012 |
Enting D, Ang J, O'Hanlon-Brown C, Kristeleit R, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, Bono JD, Spicer J. A Phase I Study of Daily Afatinib, an Irreversible Erbb Family Blocker, Combined With Weekly Paclitaxel and 2-Weekly Bevacizumab in Patients with Advanced Solid Tumours Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)33023-4 |
0.342 |
|
| 2012 |
Ng CHM, Macpherson I, Rea D, Spicer J, Bowman A, Jones A, Dowsett M, Johnston SRD, Dobbs N, Bono JSd. Phase I/II Trial of Abiraterone Acetate (AA) in Estrogen Receptor (ERα) or Androgen Receptor (AR) Positive Metastatic Breast Cancer (MBC) Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)32964-1 |
0.392 |
|
| 2012 |
Ahilathirunayagam S, Kalsi T, Husain Y, Wittenbecher F, Zohree MA, Babic-illman A, Moss C, Spicer J, Montes A, Harari D, Lal R. Chemotherapy dose density in elderly lung cancer patients requires frequent modifications: A retrospective case series from January 2011 to July 2012 Journal of Geriatric Oncology. 3. DOI: 10.1016/J.Jgo.2012.10.064 |
0.407 |
|
| 2011 |
Santis G, Angell R, Nickless G, Quinn A, Herbert A, Cane P, Spicer J, Breen R, McLean E, Tobal K. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR. Plos One. 6: e25191. PMID 21949883 DOI: 10.1371/Journal.Pone.0025191 |
0.362 |
|
| 2011 |
Lang-Lazdunski L, Bille A, Belcher E, Cane P, Landau D, Steele J, Taylor H, Spicer J. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1746-52. PMID 21876457 DOI: 10.1097/Jto.0B013E3182288Af9 |
0.384 |
|
| 2011 |
Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, Snee M, O'Brien M, Thomas G, Senan S, O'Byrne K, Kilburn LS, Spicer J, Landau D, Edwards J, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. The Lancet. Oncology. 12: 763-72. PMID 21723781 DOI: 10.1016/S1470-2045(11)70149-8 |
0.37 |
|
| 2011 |
Rudman SM, Josephs DH, Cambrook H, Karagiannis P, Gilbert AE, Dodev T, Hunt J, Koers A, Montes A, Taams L, Canevari S, Figini M, Blower PJ, Beavil AJ, Nicodemus CF, ... ... Spicer JF, et al. Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. Clinical and Experimental Allergy : Journal of the British Society For Allergy and Clinical Immunology. 41: 1400-13. PMID 21569129 DOI: 10.1111/J.1365-2222.2011.03770.X |
0.361 |
|
| 2011 |
Gilbert AE, Karagiannis P, Dodev T, Koers A, Lacy K, Josephs DH, Takhar P, Geh JL, Healy C, Harries M, Acland KM, Rudman SM, Beavil RL, Blower PJ, Beavil AJ, ... ... Spicer J, et al. Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. Plos One. 6: e19330. PMID 21559411 DOI: 10.1371/Journal.Pone.0019330 |
0.342 |
|
| 2011 |
Patel GS, Kiuchi T, Lawler K, Ofo E, Fruhwirth GO, Kelleher M, Shamil E, Zhang R, Selvin PR, Santis G, Spicer J, Woodman N, Gillett CE, Barber PR, Vojnovic B, et al. The challenges of integrating molecular imaging into the optimization of cancer therapy. Integrative Biology : Quantitative Biosciences From Nano to Macro. 3: 603-31. PMID 21541433 DOI: 10.1039/C0Ib00131G |
0.327 |
|
| 2011 |
Belcher E, Hardwick T, Lal R, Marshall S, Spicer J, Lang-Lazdunski L. Induction chemotherapy, cytoreductive surgery and intraoperative hyperthermic pleural irrigation in patients with stage IVA thymoma. Interactive Cardiovascular and Thoracic Surgery. 12: 744-7. PMID 21172935 DOI: 10.1510/Icvts.2010.255307 |
0.311 |
|
| 2011 |
Mitchell CL, O'Connor JP, Roberts C, Watson Y, Jackson A, Cheung S, Evans J, Spicer J, Harris A, Kelly C, Rudman S, Middleton M, Fielding A, Tessier J, Young H, et al. A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemotherapy and Pharmacology. 68: 631-41. PMID 21120480 DOI: 10.1007/S00280-010-1534-3 |
0.318 |
|
| 2011 |
Lang-Lazdunski L, Bille A, Belcher E, Landau D, Steele J, Taylor H, Spicer J. 51 Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and adjuvant chemotherapy in patients with malignant pleural mesothelioma. A 6-year experience Lung Cancer. 71. DOI: 10.1016/S0169-5002(11)70051-4 |
0.344 |
|
| 2010 |
Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, Vile R, Melcher A, Coffey MC, Mettinger KL, Nuovo G, Cohn DE, Phelps M, Harrington KJ, Pandha HS. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5564-72. PMID 20926400 DOI: 10.1158/1078-0432.Ccr-10-1233 |
0.42 |
|
| 2010 |
Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3965-72. PMID 20679611 DOI: 10.1200/Jco.2009.26.7278 |
0.394 |
|
| 2010 |
Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, Arkenau HT, Karavasilis V, Yap TA, Olmos D, Spicer J, Postel-Vinay S, Yin D, Lipton A, Demers L, et al. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. British Journal of Cancer. 103: 332-9. PMID 20628389 DOI: 10.1038/Sj.Bjc.6605767 |
0.389 |
|
| 2010 |
Spicer JF, Rudman SM. EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. Targeted Oncology. 5: 245-55. PMID 20574858 DOI: 10.1007/s11523-010-0140-y |
0.313 |
|
| 2010 |
Holmberg L, Sandin F, Bray F, Richards M, Spicer J, Lambe M, Klint A, Peake M, Strand TE, Linklater K, Robinson D, Møller H. National comparisons of lung cancer survival in England, Norway and Sweden 2001-2004: differences occur early in follow-up. Thorax. 65: 436-41. PMID 20435867 DOI: 10.1136/Thx.2009.124222 |
0.378 |
|
| 2009 |
Treasure T, Waller D, Tan C, Entwisle J, O'Brien M, O'Byrne K, Thomas G, Snee M, Spicer J, Landau D, Lang-Lazdunski L, Bliss J, Peckitt C, Rogers S, Marriage Née Denholm E, et al. The Mesothelioma and Radical surgery randomized controlled trial: the Mars feasibility study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: 1254-8. PMID 19661833 DOI: 10.1097/Jto.0B013E3181Ae26Ae |
0.317 |
|
| 2009 |
Reid AH, Protheroe A, Attard G, Hayward N, Vidal L, Spicer J, Shaw HM, Bone EA, Carter J, Hooftman L, Harris A, De Bono JS. A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4978-85. PMID 19638462 DOI: 10.1158/1078-0432.Ccr-09-0306 |
0.346 |
|
| 2009 |
Mukherji D, Spicer J. Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opinion On Investigational Drugs. 18: 293-301. PMID 19243280 DOI: 10.1517/13543780902762843 |
0.376 |
|
| 2009 |
Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, Knittelfelder R, Daniels TR, Hobson PS, Beavil AJ, Spicer J, Nestle FO, Penichet ML, Gould HJ, Jensen-Jarolim E, et al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunology, Immunotherapy : Cii. 58: 915-30. PMID 18941743 DOI: 10.1007/S00262-008-0607-1 |
0.317 |
|
| 2009 |
Burbridge S, Wilkie S, Davies D, Chiapero‐Stanke L, Maher J, Spicer J. Abstract C242: Development of adoptive‐T‐cell therapy for prostate cancer incorporating a novel chimeric cytokine receptor Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C242 |
0.332 |
|
| 2009 |
Stavridi F, Eestila S, Merchant S, Cane P, Spicer J. Use of erlotinib in patients selected using clinical criteria in the 2nd and 3rd line treatment of non-small cell lung cancer (NSCLC) Lung Cancer. 63. DOI: 10.1016/S0169-5002(09)70015-7 |
0.416 |
|
| 2009 |
Soffin E, Alam S, Hogan V, Rudman S, Spicer J. Treatment-associated deaths and mortality following chemotherapy for non-small cell lung cancer Lung Cancer. 63. DOI: 10.1016/S0169-5002(09)70013-3 |
0.371 |
|
| 2008 |
Kyle F, Spicer J. Targeted therapies in non-small cell lung cancer. Cancer Imaging : the Official Publication of the International Cancer Imaging Society. 8: 199-205. PMID 19028612 DOI: 10.1102/1470-7330.2008.0027 |
0.413 |
|
| 2008 |
Hughes S, Liong J, Miah A, Ahmad S, Leslie M, Harper P, Prendiville J, Shamash J, Subramaniam R, Gaya A, Spicer J, Landau D. A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 3: 648-51. PMID 18520806 DOI: 10.1097/Jto.0B013E3181757A60 |
0.446 |
|
| 2007 |
Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, Pandha H. Low Dose Metronomic Oral Cyclophosphamide for Hormone Resistant Prostate Cancer: A Phase II Study The Journal of Urology. 177: 2136-2140. PMID 17509300 DOI: 10.1016/J.Juro.2007.01.143 |
0.379 |
|
| 2007 |
Spicer J, Chowdhury S, Harper P. Targeting novel and established therapies for non-small cell lung cancer. Cancer Letters. 250: 9-16. PMID 17030089 DOI: 10.1016/J.Canlet.2006.09.001 |
0.435 |
|
| 2007 |
Spicer J, Ellis P. Towards optimal endocrine therapy for hormone-sensitive breast cancer: Initial versus sequential adjuvant aromatase inhibition Cancer Letters. 248: 165-174. PMID 16919870 DOI: 10.1016/J.Canlet.2006.07.002 |
0.321 |
|
| 2007 |
Spicer J, Futreal A, Bono JD. Pharmacogenomics of non-small cell lung cancer Current Pharmacogenomics. 5: 228-234. DOI: 10.2174/157016007781669178 |
0.374 |
|
| 2007 |
Protheroe A, Reid A, Attard G, Davies A, Spicer J, Vidal L, Bone E, Hooftman L, Harris A, De-Bono J. First in-human phase 1 trial of a novel amino-peptidase inhibitor, CHR-2797 Journal of Clinical Oncology. 25: 3537-3537. DOI: 10.1200/Jco.2007.25.18_Suppl.3537 |
0.383 |
|
| 2007 |
Reid AH, Tang A, Spicer J, Gallerani E, Mears D, Settatree S, Yap TA, Puchalski T, Harrison M, De-Bono JS. An open, pharmacokinetic (PK) and mass balance study of 14C-AZD2171, incorporating DCE-CT evaluations Journal of Clinical Oncology. 25: 14140-14140. DOI: 10.1200/Jco.2007.25.18_Suppl.14140 |
0.319 |
|
| 2007 |
Shaw HM, Molife LR, Spicer J, Karavasilis V, Marriott C, Ong TJ, Tate L, Brendel E, Christensen O, Bono JSd. A phase Ib study of telatinib (BAY 57–9352), a VEGFR-2 inhibitor, in combination with docetaxel in patients with advanced solid tumours Journal of Clinical Oncology. 25: 14035-14035. DOI: 10.1200/Jco.2007.25.18_Suppl.14035 |
0.325 |
|
| 2007 |
Spicer J, Calvert H, Vidal L, Azribi F, Perrett R, Shahidi M, Temple G, Futreal A, Bono JD, Plummer R. D7-02: Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR Journal of Thoracic Oncology. 2. DOI: 10.1097/01.Jto.0000283293.26207.0A |
0.38 |
|
| 2007 |
Plummer R, Vidal L, Perrett R, Spicer J, Stopfer P, Shahidi M, Temple G, Futreal A, Calvert H, Bono Jd. 703 POSTER A phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor Ejc Supplements. 5: 108. DOI: 10.1016/S1359-6349(07)70502-5 |
0.319 |
|
| 2006 |
Reid A, Protheroe A, Attard G, Cowsill C, Spicer J, Vidal L, Bone E, Hooftman L, Harris A, De-Bono JS. A phase 1 dose finding study of CHR-2797, an inhibitor of M1 aminopeptidases, in patients with advanced solid tumours Journal of Clinical Oncology. 24: 3053-3053. DOI: 10.1200/Jco.2006.24.18_Suppl.3053 |
0.387 |
|
| 2006 |
Attard G, Fong PC, Molife R, Reade S, Shaw H, Reid A, Spicer J, Hamlin J, Gualberto A, Bono JSD. Phase I trial involving the pharmacodynamic (PD) study of circulating tumour cells, of CP-751,871 (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R), with docetaxel (D) in patients (p) with advanced cancer Journal of Clinical Oncology. 24: 3023-3023. DOI: 10.1200/Jco.2006.24.18_Suppl.3023 |
0.321 |
|
| 2006 |
de Bono J, Fong P, Boss D, Spicer J, Roelvink M, Tutt A, Mortimer P, O'Connor M, M J, Kaye S. 503 POSTER Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evalutation of an oral small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), Ku in patients (p) with advance tumours European Journal of Cancer Supplements. 4: 153. DOI: 10.1016/S1359-6349(06)70508-0 |
0.317 |
|
| 2006 |
Fong PC, Molife RL, Spicer J, Yap TA, Settatree S, Digue L, Attard G, Karavasilis V, Gualberto A, Bono JSd. 196 POSTER A phase I trial incorporating the pharmacodynamic (PD) study of circulating tumour cells (CTC) of CP-751,871 (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R), in combination with docetaxel (D) in patients (p) with advanced cancer Ejc Supplements. 4: 61-62. DOI: 10.1016/S1359-6349(06)70201-4 |
0.347 |
|
| 2006 |
Spicer J, Banerji U, Hanwell J, Judson I. Stable disease for four years in metastatic malignant melanoma treated with the heat shock protein inhibitor 17-AAG Targeted Oncology. 1: 54-55. DOI: 10.1007/S11523-005-0008-8 |
0.34 |
|
| 2005 |
Cheong KA, Chrystal K, Spicer J, Harper PG. A single centre retrospective review of oral cyclophosphamide in hormone-refractory prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4781. PMID 27943818 DOI: 10.1200/Jco.2005.23.16_Suppl.4781 |
0.382 |
|
| 2005 |
Spicer J, Harper P. Targeted therapies for non-small cell lung cancer International Journal of Clinical Practice. 59: 1055-1062. PMID 16115182 DOI: 10.1111/J.1742-1241.2005.00622.X |
0.401 |
|
| 2005 |
Spicer J, Harries M, Ellis P. Adjuvant trastuzumab for HER2-positive breast cancer. Lancet (London, England). 366: 634. PMID 16112298 DOI: 10.1016/S0140-6736(05)67134-6 |
0.353 |
|
| 2005 |
Cheong K, Spicer J, Chowdhury S, Harper P. Combination therapy versus single agent chemotherapy in non-small cell lung cancer. Expert Opinion On Pharmacotherapy. 6: 1693-700. PMID 16086655 DOI: 10.1517/14656566.6.10.1693 |
0.404 |
|
| 2005 |
Spicer J, Plunkett T, Somaiah N, Chan S, Kendall A, Bolunwu N, Pandha H. Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer. Prostate Cancer and Prostatic Diseases. 8: 364-8. PMID 16077679 DOI: 10.1038/Sj.Pcan.4500821 |
0.38 |
|
| 2004 |
Spicer J, Quatan N, Plunkett T, Pandha H. Cellular immunotherapy for cancer: current concepts and clinical perspectives Monitoring immune responses and clinical trials: part II. Clinical Oncology. 16: 395-404. PMID 15487131 DOI: 10.1016/J.Clon.2004.03.014 |
0.306 |
|
| 2004 |
Quatan N, Spicer J, Plunkett T, Pandha H. Cellular immunotherapy for cancer: current concepts and clinical perspectives scientific basis and approaches for therapeutic cancer vaccines. Part I. Clinical Oncology. 16: 356-365. PMID 15341440 DOI: 10.1016/J.Clon.2004.03.013 |
0.37 |
|
| 2004 |
Spicer J, Smith P, Maclennan K, Hoskin P, Hancock B, Linch D, Pettengell R. Long-term follow-up of patients treated with radiotherapy alone for early-stage histologically aggressive non-Hodgkin's lymphoma. British Journal of Cancer. 90: 1151-5. PMID 15026794 DOI: 10.1038/Sj.Bjc.6601675 |
0.354 |
|
| Show low-probability matches. |